9 Things to Know About Low-Dose Naltrexone as an Emerging Option for Menopause Pain and Inflammation
When the pain stopped making sense — when it moved around, got worse for no clear reason, and no one could find anything 'wrong' on a scan — that's the moment a lot of women start falling through the cracks of conventional care. LDN came up in so many of those conversations, always in hushed tones, always from women who felt like they'd stumbled onto something they weren't supposed to know about yet. That secrecy shouldn't exist — it deserves a proper, clear-eyed look.
Learn more about Rose →LDN is the same drug as naltrexone — just at a fraction of the standard dose
Naltrexone was FDA-approved in the 1980s at doses of 50mg to treat opioid and alcohol dependence by fully blocking opioid receptors. Low-dose naltrexone uses doses typically between 1.5mg and 4.5mg, which creates a very different and more nuanced effect on the immune and nervous systems. Because it's used so far below the approved dose, it's prescribed off-label and must usually be compounded by a specialist pharmacy.
The mechanism that matters for pain involves microglial cells in the brain
At low doses, naltrexone temporarily blocks opioid receptors for just a few hours, which triggers a rebound effect — the body compensates by upregulating its own endorphin production. Separately, and perhaps more importantly for pain, LDN appears to inhibit microglial activation: microglia are the immune cells of the central nervous system, and when they become chronically overactivated, they amplify pain signals and drive neuroinflammation. This anti-neuroinflammatory action is the core reason researchers are interested in LDN for conditions involving central sensitization.
Estrogen decline directly fuels the neuroinflammation LDN is trying to calm
Estrogen has well-documented anti-inflammatory effects in the central nervous system, including direct suppression of microglial activation. As estrogen falls during perimenopause and menopause, microglial cells can shift into a more reactive, pro-inflammatory state — which helps explain why conditions like fibromyalgia, migraines, and autoimmune diseases often worsen significantly at this life stage. LDN's proposed mechanism targets almost exactly this pathway, which is why the timing of interest in it for menopausal women is not coincidental.
The strongest human evidence for LDN so far comes from fibromyalgia trials
A small but carefully designed randomized crossover trial from Stanford (Younger et al., 2013) found that LDN reduced fibromyalgia pain scores by roughly 30% compared to placebo, with participants also reporting better mood and fatigue levels. A follow-up observational study supported the finding that women specifically showed stronger responses, which researchers linked to baseline hormonal differences. These are small trials and the evidence doesn't yet meet the bar for a strong clinical recommendation, but the signal is consistent enough that fibromyalgia specialists now regularly discuss LDN as an option.
Autoimmune conditions that flare at menopause are also being studied
Multiple sclerosis, Crohn's disease, lupus, and rheumatoid arthritis all have documented associations with hormonal shifts at menopause, and all have small published studies or case series examining LDN. The proposed reason is the same: LDN's ability to modulate Toll-like receptor 4 (TLR4) signaling on immune cells may reduce the excessive immune activation that drives autoimmune flares. Evidence here is at the C-to-B boundary — promising, worth discussing, but not yet practice-changing without larger trials.
Central sensitization — the 'volume turned up too high' pain problem — is where LDN may help most
Central sensitization is a state in which the central nervous system becomes hypersensitized, interpreting normal signals as painful and amplifying all pain input. It underlies not just fibromyalgia but also conditions like chronic pelvic pain, interstitial cystitis, and some forms of vulvodynia — all of which can emerge or worsen in perimenopause. LDN's anti-microglial action directly targets the neuroinflammatory maintenance of central sensitization, and clinicians working in this space are increasingly including it in treatment conversations, though evidence specific to menopause-related central sensitization remains limited.
The side effect profile is generally mild, but sleep disruption is a real issue
Because LDN is taken at night and works partly through a transient opioid receptor blockade during sleep hours, vivid dreams and initial sleep disruption are the most commonly reported side effects — typically occurring in the first two to four weeks before the body adjusts. Nausea and headaches are occasionally reported at the start of treatment and usually resolve. Unlike many pain medications, LDN carries no addiction potential, no organ toxicity at these doses, and no meaningful drug interactions for most people — though it absolutely cannot be taken by anyone using opioid medications, as it will precipitate immediate withdrawal.
LDN requires a compounding pharmacy because it's not made commercially at low doses
Standard naltrexone tablets come in 50mg form and cannot simply be split down to 1.5–4.5mg with reliable accuracy, so LDN must be prepared by a compounding pharmacy in capsule or liquid form. This means it won't be covered by most insurance plans and costs typically range from $30–$60 per month out of pocket depending on the pharmacy and country. When asking a prescriber about LDN, it helps to come prepared knowing this — some doctors are unfamiliar with the compounding requirement and may mistakenly believe it isn't available.
Here are the specific questions worth bringing to a doctor or specialist
The most productive framing is to ask whether central sensitization or neuroinflammation might be contributing to current symptoms, and whether LDN has been considered in that context — rather than simply requesting the drug by name. It's also worth asking whether the prescribing doctor has experience with LDN or can refer to someone who does, since familiarity with dosing titration (usually starting at 0.5–1.5mg and increasing slowly over weeks) significantly affects outcomes. Bringing a summary of the Younger fibromyalgia trials or the LDN Research Trust's published evidence review to the appointment is a reasonable and welcomed move with most open-minded clinicians.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.